Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Status:
Not yet recruiting
Trial end date:
2038-10-15
Target enrollment:
Participant gender:
Summary
Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with
2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome
patients during and following daily intake for 2 years.